Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer

HIGHLIGHTS

• who: Jodi M. Carter from the This study was conducted in accordance with recognized ethical guidelines, including the US. Common Rule. The FinXX study was approved by an Institutional Review Board at the Helsinki University Hospital (approvals, and HUS/903/2017). The patients who participated in the FinXX trial (NCT00114816) signed a written informed consent to the trial participation and consent to allow the use of their tumor tissue for FinXX trial-related research purposes. Analysis of Mayo Clinic TNBC samples was approved by the Mayo Clinic Institutional Review Board. Written informed consent was obtained from all . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.